1 |
CHRNA3
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
2 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
3 |
CHRNA4
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D08669
D08669
|
Varenicline
| 3件: 6 6, 18, 53 |
4 |
CHRNA7
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
5 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
6 |
CHRNB2
| 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation | D08669
D08669
|
Varenicline
| 3件: 6 6, 18, 53 |
7 |
CHRNB4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
8 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
9 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
10 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
11 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00235
D00235
|
Atenolol
| 1件: 167 167 |
12 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
13 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
14 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00432
D00432
|
Nadolol
| 1件: 6 6 |
15 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
16 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02342
D02342
|
Bisoprolol
| 4件: 58 58, 67, 86, 113 |
17 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
18 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02358
D02358
|
Metoprolol
| 6件: 17 17, 57, 58, 113, 193, 226 |
19 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02910
D02910
|
Amiodarone
| 2件: 28 28, 127 |
20 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03879
D03879
|
Dobutamine
| 4件: 57 57, 58, 86, 215 |
21 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D05127
D05127
|
Nebivolol
| 4件: 17 17, 85, 113, 167 |
22 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07660
D07660
|
Celiprolol
| 1件: 168 168 |
23 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D07916
D07916
|
Esmolol
| 1件: 58 58 |
24 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
25 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
26 |
ADRB1
| 7件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
27 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
28 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
29 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
30 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| 4件: 57 57, 86, 113, 210 |
31 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00378
D00378
|
Timolol
| 2件: 157 157, 227 |
32 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00432
D00432
|
Nadolol
| 1件: 6 6 |
33 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
34 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| 12件: 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 |
35 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02151
D02151
|
Tulobuterol
| 1件: 6 6 |
36 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
37 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D05792
D05792
|
Salmeterol
| 1件: 299 299 |
38 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07713
D07713
|
Clenbuterol
| 5件: 1 1, 2, 6, 13, 256 |
39 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D07990
D07990
|
Formoterol
| 3件: 85 85, 228, 299 |
40 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08092
D08092
|
Isoxsuprine
| 1件: 13 13 |
41 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08124
D08124
|
Levosalbutamol
| 1件: 49 49 |
42 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
43 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
44 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08570
D08570
|
Terbutaline
| 1件: 118 118 |
45 |
ADRB2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08600
D08600
|
Timolol
| 2件: 157 157, 227 |
46 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00076
D00076
|
Norepinephrine
| 2件: 22 22, 296 |
47 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| 3件: 46 46, 70, 96 |
48 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00124
D00124
|
Ephedrine
| 1件: 11 11 |
49 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D01277
D01277
|
Droxidopa
| 5件: 5 5, 6, 17, 169, 170 |
50 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02349
D02349
|
Dipivefrin
| 1件: 6 6 |
51 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08443
D08443
|
Propranolol
| 6件: 6 6, 158, 167, 227, 278, 296 |
52 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D08449
D08449
|
Pseudoephedrine
| 1件: 17 17 |
53 |
ADRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D09535
D09535
|
Mirabegron
| 4件: 6 6, 13, 53, 226 |
54 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01977
D01977
|
Gefitinib
| 1件: 75 75 |
55 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D03455
D03455
|
Cetuximab
| 2件: 51 51, 86 |
56 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D07907
D07907
|
Erlotinib
| 1件: 94 94 |
57 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08108
D08108
|
Lapatinib
| 3件: 34 34, 74, 75 |
58 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08950
D08950
|
Neratinib
| 1件: 34 34 |
59 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11251
D11251
|
Icotinib
| 1件: 34 34 |
60 |
EGFR
| 42件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11772
D11772
|
Tesevatinib
| 1件: 67 67 |
61 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
62 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
63 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D00289
D00289
|
Danazol
| 5件: 60 60, 63, 64, 65, 285 |
64 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D00554
D00554
|
Ethinylestradiol
| 4件: 13 13, 46, 49, 299 |
65 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D00575
D00575
|
Mestranol
| 2件: 46 46, 49 |
66 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D01161
D01161
|
Fulvestrant
| 2件: 49 49, 86 |
67 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D01413
D01413
|
Estradiol valerate
| 1件: 65 65 |
68 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
69 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D02367
D02367
|
Desogestrel
| 1件: 230 230 |
70 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D07726
D07726
|
Clomifene
| 1件: 74 74 |
71 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
72 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D08465
D08465
|
Raloxifene
| 1件: 46 46 |
73 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D08559
D08559
|
Tamoxifen
| 3件: 2 2, 113, 227 |
74 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D11513
D11513
|
Estetrol
| 1件: 53 53 |
75 |
ESR1
| 8件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation | D11514
D11514
|
Estetrol
| 1件: 53 53 |
76 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D00105
D00105
|
Estradiol
| 7件: 13 13, 46, 49, 65, 76, 226, 299 |
77 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D00185
D00185
|
Estriol
| 2件: 13 13, 227 |
78 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D00575
D00575
|
Mestranol
| 2件: 46 46, 49 |
79 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D01161
D01161
|
Fulvestrant
| 2件: 49 49, 86 |
80 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D01413
D01413
|
Estradiol valerate
| 1件: 65 65 |
81 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D01986
D01986
|
Estriol
| 2件: 13 13, 227 |
82 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D07726
D07726
|
Clomifene
| 1件: 74 74 |
83 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
84 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D08465
D08465
|
Raloxifene
| 1件: 46 46 |
85 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D08559
D08559
|
Tamoxifen
| 3件: 2 2, 113, 227 |
86 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D11513
D11513
|
Estetrol
| 1件: 53 53 |
87 |
ESR2
| 6件: Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation | D11514
D11514
|
Estetrol
| 1件: 53 53 |
88 |
MTOR
| 40件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| 40件: 2 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 |
89 |
MTOR
| 40件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D02714
D02714
|
Everolimus
| 9件: 34 34, 67, 89, 96, 137, 157, 158, 228, 277 |
90 |
MTOR
| 40件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D06068
D06068
|
Temsirolimus
| 1件: 13 13 |
91 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00075
D00075
|
Testosterone
| 8件: 1 1, 2, 3, 13, 60, 76, 78, 113 |
92 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00289
D00289
|
Danazol
| 5件: 60 60, 63, 64, 65, 285 |
93 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00444
D00444
|
Stanozolol
| 1件: 60 60 |
94 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00462
D00462
|
Oxandrolone
| 2件: 211 211, 285 |
95 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00586
D00586
|
Flutamide
| 1件: 81 81 |
96 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00955
D00955
|
Nandrolone decanoate
| 2件: 60 60, 85 |
97 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00958
D00958
|
Testosterone enanthate
| 1件: 113 113 |
98 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00959
D00959
|
Testosterone propionate
| 1件: 113 113 |
99 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D03338
D03338
|
Calusterone
| 1件: 2 2 |
100 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D06087
D06087
|
Testosterone undecanoate
| 2件: 13 13, 60 |
101 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08250
D08250
|
Nandrolone
| 2件: 60 60, 85 |
102 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08409
D08409
|
Prasterone
| 6件: 49 49, 53, 83, 86, 96, 113 |
103 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08573
D08573
|
Testosterone decanoate
| 1件: 113 113 |
104 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08574
D08574
|
Testosterone phenylpropionate
| 1件: 113 113 |
105 |
JAK2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09959
D09959
|
Ruxolitinib
| 3件: 60 60, 65, 228 |
106 |
JAK2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
107 |
JAK2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10308
D10308
|
Baricitinib
| 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
108 |
JAK2
| 22件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
109 |
NFKB1
| 62件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01146
D01146
|
Iguratimod
| 5件: 46 46, 51, 53, 271, 300 |
110 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00066
D00066
|
Progesterone
| 2件: 76 76, 299 |
111 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00182
D00182
|
Norethisterone
| 4件: 13 13, 46, 49, 299 |
112 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00289
D00289
|
Danazol
| 5件: 60 60, 63, 64, 65, 285 |
113 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00585
D00585
|
Mifepristone
| 1件: 75 75 |
114 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00950
D00950
|
Levonorgestrel
| 1件: 13 13 |
115 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00951
D00951
|
Medroxyprogesterone acetate
| 8件: 13 13, 35, 46, 49, 50, 51, 60, 107 |
116 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D00952
D00952
|
Megestrol acetate
| 1件: 76 76 |
117 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D01217
D01217
|
Dydrogesterone
| 1件: 13 13 |
118 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D02367
D02367
|
Desogestrel
| 1件: 230 230 |
119 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D05209
D05209
|
Norgestimate
| 1件: 299 299 |
120 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D07222
D07222
|
Nomegestrol
| 1件: 13 13 |
121 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D08281
D08281
|
Nomegestrol acetate
| 1件: 13 13 |
122 |
PGR
| 4件: Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation | D09567
D09567
|
Ulipristal
| 1件: 10 10 |
123 |
PIK3CA
| 87件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11011
D11011
|
Alpelisib
| 1件: 138 138 |
124 |
PIK3CA
| 87件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
125 |
PIK3CB
| 87件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
126 |
PIK3CD
| 87件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
127 |
PIK3CD
| 87件: Inositol phosphate metabolism Inositol phosphate metabolism, Metabolic pathways, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Cholinergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, GnRH secretion, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Small cell lung cancer, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
128 |
PPARA
| 7件: PPAR signaling pathway PPAR signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D00565
D00565
|
Fenofibrate
| 6件: 8 8, 79, 93, 94, 97, 265 |
129 |
PPARA
| 7件: PPAR signaling pathway PPAR signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D01366
D01366
|
Bezafibrate
| 7件: 20 20, 93, 94, 160, 296, 316, 324 |
130 |
PPARA
| 7件: PPAR signaling pathway PPAR signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D10711
D10711
|
Pemafibrate
| 1件: 93 93 |
131 |
PPARA
| 7件: PPAR signaling pathway PPAR signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D11208
D11208
|
Elafibranor
| 2件: 93 93, 94 |
132 |
CHRNA9
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation | D03365
D03365
|
Nicotine
| 3件: 6 6, 13, 84 |
133 |
PRKCB
| 62件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Focal adhesion, Gap junction, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Fc gamma R-mediated phagocytosis, Leukocyte transendothelial migration, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Long-term depression, Inflammatory mediator regulation of TRP channels, Insulin secretion, GnRH signaling pathway, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Insulin resistance, Growth hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Leishmaniasis, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Glioma, Non-small cell lung cancer, Hepatocellular carcinoma, Choline metabolism in cancer, Diabetic cardiomyopathy | D11935
D11935
|
Enzastaurin
| 1件: 168 168 |
134 |
MAP2K1
| 75件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
135 |
MAP2K1
| 75件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
136 |
MAP2K1
| 75件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
137 |
MAP2K1
| 75件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
138 |
MAP2K1
| 75件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Cholinergic synapse, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
139 |
MAP2K2
| 64件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
140 |
MAP2K2
| 64件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
141 |
MAP2K2
| 64件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
142 |
MAP2K2
| 64件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
143 |
MAP2K2
| 64件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
144 |
RAF1
| 67件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Chronic myeloid leukemia, Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
145 |
BCL2
| 37件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, Hedgehog signaling pathway, Focal adhesion, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Neurotrophin signaling pathway, Cholinergic synapse, Estrogen signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Hepatitis B, Measles, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Prostate cancer, Small cell lung cancer, Gastric cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10679
D10679
|
Venetoclax
| 1件: 28 28 |
146 |
RELA
| 62件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Chemical carcinogenesis - receptor activation, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D12181
D12181
|
Edasalonexent
| 1件: 113 113 |
147 |
RXRA
| 15件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
148 |
RXRA
| 15件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
149 |
RXRA
| 15件: PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
150 |
RXRB
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
151 |
RXRB
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
152 |
RXRB
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
153 |
RXRG
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02754
D02754
|
Acitretin
| 1件: 37 37 |
154 |
RXRG
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D02815
D02815
|
Alitretinoin
| 1件: 49 49 |
155 |
RXRG
| 12件: PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| 2件: 13 13, 75 |
156 |
SRC
| 36件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, VEGF signaling pathway, Focal adhesion, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03252
D03252
|
Bosutinib
| 2件: 2 2, 67 |
157 |
SRC
| 36件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, VEGF signaling pathway, Focal adhesion, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
158 |
SRC
| 36件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, VEGF signaling pathway, Focal adhesion, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
159 |
SRC
| 36件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, VEGF signaling pathway, Focal adhesion, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09664
D09664
|
Saracatinib
| 3件: 6 6, 89, 272 |
160 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00122
D00122
|
Calcifediol
| 2件: 113 113, 299 |
161 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00129
D00129
|
Calcitriol
| 9件: 18 18, 37, 46, 49, 66, 96, 158, 235, 326 |
162 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00187
D00187
|
Ergocalciferol
| 6件: 46 46, 49, 84, 96, 97, 299 |
163 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| 24件: 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
164 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00299
D00299
|
Dihydrotachysterol
| 2件: 6 6, 85 |
165 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00930
D00930
|
Paricalcitol
| 5件: 19 19, 66, 218, 238, 298 |
166 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D01125
D01125
|
Calcipotriol
| 2件: 36 36, 51 |
167 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D01518
D01518
|
Alfacalcidol
| 8件: 41 41, 46, 49, 50, 96, 107, 235, 238 |
168 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D07578
D07578
|
Eldecalcitol
| 1件: 46 46 |
169 |
VEGFA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis | D05697
D05697
|
Ranibizumab
| 4件: 34 34, 166, 227, 301 |
170 |
VEGFA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis | D06409
D06409
|
Bevacizumab
| 6件: 13 13, 34, 85, 87, 227, 280 |
171 |
VEGFA
| 20件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis | D09574
D09574
|
Aflibercept
| 2件: 90 90, 166 |
172 |
CACNA1B
| 14件: MAPK signaling pathway MAPK signaling pathway, Synaptic vesicle cycle, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Type II diabetes mellitus, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Nicotine addiction, Chemical carcinogenesis - receptor activation | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
173 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
174 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
175 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
176 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
177 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
178 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
179 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
180 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
181 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
182 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
183 |
CACNA1C
| 25件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
184 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
185 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
186 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
187 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
188 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
189 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
190 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
191 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
192 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
193 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
194 |
CACNA1D
| 24件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
195 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
196 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
197 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
198 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
199 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
200 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
201 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
202 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
203 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
204 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
205 |
CACNA1F
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
206 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00349
D00349
|
Isradipine
| 1件: 6 6 |
207 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
208 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
209 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
210 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
211 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
212 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
213 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
214 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
215 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
216 |
CACNA1S
| 19件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Dilated cardiomyopathy | D08441
D08441
|
Propiverine
| 1件: 226 226 |
217 |
TNFSF11
| 7件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Rheumatoid arthritis | D03684
D03684
|
Denosumab
| 8件: 46 46, 50, 70, 93, 95, 96, 274, 299 |